{
    "paper_id": "42f0c7c586d90d9f1385e2d6cfc21d181a68ff7e",
    "metadata": {
        "title": "",
        "authors": [
            {
                "first": "Claudia",
                "middle": [],
                "last": "Mendoza-Pinto",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Mario",
                "middle": [],
                "last": "Garc\u00eda-Carrasco",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Pamela",
                "middle": [
                    "Mungu\u00eda"
                ],
                "last": "Realpozo",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Socorro",
                "middle": [],
                "last": "M\u00e9ndez-Mart\u00ednez",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "alteraci\u00f3n puede estar presente en diversas entidades cl\u00ednicas incluyendo en el \u00e1mbito de la reumatolog\u00eda, como es la Enfermedad de Still, artritis idiop\u00e1tica juvenil sist\u00e9mica, lupus eritematoso sist\u00e9mica (LES), s\u00edndrome antifosfol\u00edpidos (SAF) en su variedad catastr\u00f3fica. El SLC participa en la inmunopatog\u00e9nesis de muchos procesos patol\u00f3gicos, como el SIRA, sepsis, s\u00edndrome del macr\u00f3fago activado (SMA), etc., varias de ellas descritas en el s\u00edndrome respiratorio agudo grave (SARS por sus siglas en ingl\u00e9s), el s\u00edndrome respiratorio de oriente medio (MERS, por sus siglas en ingl\u00e9s) y tambi\u00e9n en la nueva infecci\u00f3n COVID-19 3 . Mientras que el tratamiento dirigido en contra el virus es lo deseado, el tratamiento de la respuesta sist\u00e9mica es posiblemente el aspecto m\u00e1s importante para el cuidado del paciente y debe ser visto en forma agresiva. Finalmente, los pacientes con COVID-19 que desarrollan un cuadro grave, pueden presentar un patr\u00f3n procoagulante 4 . Por lo en esta revisi\u00f3n se sintetiza la evidencia relacionada a terapias con un papel anti-inflamatorio que pueden jugar un papel relevante en el manejo de pacientes con COVID-19 grave, mencionado brevemente el papel de la terapia anti-tromb\u00f3tica en el tratamiento de pacientes complicados.",
            "cite_spans": [
                {
                    "start": 629,
                    "end": 630,
                    "text": "3",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 965,
                    "end": 966,
                    "text": "4",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Los glucocorticoides (GC) ha sido uno de los agentes anti-inflamatorios m\u00e1s utilizados, son com\u00fanmente prescritos en el tratamiento de pacientes con COVID-19 (72% en la UCI) 5 . Sin embargo, como ha sido mencionado en las gu\u00edas Chinas de COVID-19 6 , los m\u00e9dicos necesitan ser cuidadosos en el uso de los GC debido a sus beneficios inciertos en el contexto de la infecci\u00f3n respiratoria viral. Varios estudios han reportado resultados inferiores en pacientes con SARS tratados con GC 7 , debido al retraso en la depuraci\u00f3n viral.",
            "cite_spans": [
                {
                    "start": 174,
                    "end": 175,
                    "text": "5",
                    "ref_id": null
                },
                {
                    "start": 247,
                    "end": 248,
                    "text": "6",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": "Glucocorticoides"
        },
        {
            "text": "Otra preocupaci\u00f3n de los GC son los efectos adversos a corto y largo plazo.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Glucocorticoides"
        },
        {
            "text": "Publicaciones recientes han tra\u00eddo la atenci\u00f3n el posible efecto ben\u00e9fico de hidroxicloroquina (HCQ) y cloroquina (CLQ) en el tratamiento de pacientes infectados con nuevo coronavirus COVID-19. Se ha observado que el crecimiento de varios diferentes virus (incluyendo SARS coronavirus) puede ser inhibido en cultivo celulares tanto por la CLQ como por la HCQ. Adem\u00e1s, estos medicamentos son bases d\u00e9biles que pueden afectar ves\u00edculas \u00e1cidas e inhibir varias enzimas. Esta caracter\u00edstica permite inhibir la entrada viral a la c\u00e9lulas cuando la endocitosis es dependiente del pH. Tambi\u00e9n inhiben a la enzima glicosil transferasa (inhibici\u00f3n de la glicosilaci\u00f3n del virus), modificaciones virales post-transcripci\u00f3n y replicaci\u00f3n de algunas familias virales. Como es sabido que la infecci\u00f3n COVID-19 puede llevar en algunas ocasiones a tener cuadros graves con s\u00edndrome respiratorio agudo grave, el cual puede ser debido en parte al incremento de citosinas pro-inflamatorias como IL-6 y el factor de necrosis tumoral alfa (TNF-\uf061). En este contexto, se ha encontrado que los antimal\u00e1ricos inhiben citocinas pro-inflamatorias como la IL-6 y TNF-\uf061. La CLQ es altamente efectiva en combinaci\u00f3n con remdesivir en el control de la infecci\u00f3n COVID-19 8 ",
            "cite_spans": [
                {
                    "start": 1241,
                    "end": 1242,
                    "text": "8",
                    "ref_id": "BIBREF8"
                }
            ],
            "ref_spans": [],
            "section": "Antimal\u00e1ricos (Cloroquina e Hidroxicloroquina)"
        },
        {
            "text": "Actualmente existe ya alguna evidencia en seres humanos. En un estudio abierto observacional llevado a cabo en Francia evaluaron el papel de la HCQ en combinaci\u00f3n con azitromicina sobre la carga viral respiratoria en 20 pacientes COVID-19 positivos comparado con 16 controles 9 . Se mostr\u00f3 una reducci\u00f3n significativa de la carga viral (70% al s\u00e9ptimo d\u00eda) comparado con controles. Cuando se a\u00f1adi\u00f3 azitromicina se encontr\u00f3 una eliminaci\u00f3n m\u00e1s eficiente del virus (reducci\u00f3n del 100%). Gao y col., describieron resultados en 100 pacientes de China donde hab\u00edan demostraron la superioridad de CLQ sobre tratamiento control tomando en cuenta la inhibici\u00f3n de exacerbaci\u00f3n de neumon\u00eda, mejora en los hallazgos de imagen del pulm\u00f3n, promoviendo la conversi\u00f3n negativa del virus y el acortamiento en el curso de la enfermedad 10 . Sin embargo, los detalles de este estudio no se conocen con profundidad. En una comunicaci\u00f3n reciente se inform\u00f3 resultados de un an\u00e1lisis retrospectivo de 368 pacientes hospitalizados con la infecci\u00f3n SARSCov-2 Page 4 of 17 J o u r n a l P r e -p r o o f 4 confirmada (Administraci\u00f3n de la Salud de Veteranos de Estados Unidos) de la evaluaci\u00f3n a la exposici\u00f3n a HCQ sola o en combinaci\u00f3n con azitromicina 11 . Las tasas de mortalidad en los grupos de HCQ sola, HQC combinada y sin HQC, fueron de 27.8%, 22.1% y 11.4%, respectivamente. Las tasa de ventilaci\u00f3n en los grupos de HCQ, HCQ combinada y sin HCQ fueron de 13.3%, 6.9% y 14.1%, respectivamente. En este estudio no se encontr\u00f3 evidencia de que el uso de HCQ sola o combinada reduzca el riesgo de ventilaci\u00f3n mec\u00e1nica en pacientes hospitalizados con COVID-19 y que los pacientes recibiendo HCQ sola tuvieron la mayor tasa de mortalidad. Estos hallazgos destacan la importancia de esperar los resultados de estudios prospectivos aleatorizados que se est\u00e1n llevando a cabo antes de adoptar ampliamente estos f\u00e1rmacos. Actualmente hay alrededor de 14 ensayos cl\u00ednicos registrados para probar el beneficio de antimal\u00e1ricos. Aunque los antimal\u00e1ricos son f\u00e1rmacos relativamente seguros, recordar que sus efectos m\u00e1s frecuentes son los gastrointestinales, prurito y cambios d\u00e9rmicos en el 10% de los pacientes. Los efectos m\u00e1s graves son de baja incidencia como la cardiomiotoxicidad, la neuromiopat\u00eda y retinopat\u00eda irreversible (grandes dosis y a largo plazo).",
            "cite_spans": [
                {
                    "start": 821,
                    "end": 823,
                    "text": "10",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 1233,
                    "end": 1235,
                    "text": "11",
                    "ref_id": "BIBREF12"
                }
            ],
            "ref_spans": [],
            "section": "in vitro."
        },
        {
            "text": "Recientemente, ha surgido mucho inter\u00e9s en la posibilidad de utilizar tocilizumab, un anticuerpos humanizado dirigido al receptor de la interleucina 6 (IL-6), con el argumento de prevenir o tratar la tormenta de citocinas que se ha observado en pacientes que progresa a colapso cardiovascular, disfunci\u00f3n multiorg\u00e1nico y muerte 12 . Las citocinas inflamatorias y quimiocinas, incluyendo la IL-6, IL-1\u03b2, prote\u00edna inducida 10 (IP10) y prote\u00edna quimiot\u00e1ctica de monocitos 1 (MCP-1), se han encontrado significativamente elevadas en pacientes COVID-19, y estando con mayor frecuencia elevados en pacientes graves que en pacientes no graves 13 . En pacientes COVID-19, con citocinas inflamatorias elevadas, la patolog\u00eda post- Los estudios han mostrado que SIRA ocurre en algunos pacientes con SARS a pesar de una carga viral disminuida, sugiriendo que una respuesta inmune exuberante mas que la virulencia viral es posiblemente responsable para la patolog\u00eda a nivel tisular. Por lo tanto la terapia antiviral sola pudiera no ser suficiente 15 . Como se mencion\u00f3 previamente una de las citocinas que juega un papel en la patog\u00e9nesis en pacientes con COVID-19 grave es la IL-6, adem\u00e1s, se ha sugerido como un biomarcador de enfermedad grave 16 , por lo que bloqueo puede ser una estrategia prometedora para el SLC inducido por COVID.",
            "cite_spans": [
                {
                    "start": 636,
                    "end": 638,
                    "text": "13",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 1035,
                    "end": 1037,
                    "text": "15",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 1234,
                    "end": 1236,
                    "text": "16",
                    "ref_id": "BIBREF16"
                }
            ],
            "ref_spans": [],
            "section": "Tocilizumab, Inhibidor de la Interleucina 6 (IL-6)."
        },
        {
            "text": "La IL-6 es esencial para la generaci\u00f3n de linfocitos T colaboradores 17 (Th17), en la interacci\u00f3n de las c\u00e9lulas dendr\u00edticas-linfocito T 17 . Por lo que la elevaci\u00f3n de IL-6 puede explicar la excesiva activaci\u00f3n de Th17 observada en pacientes COVID-19, como lo report\u00f3 Xu y col. 14 . Aunque no hay disponible datos del bloqueo de IL-6 en SLC inducida por la infecci\u00f3n viral, estudios en animales de SARS-CoV han demostrado que inhiben el factor nuclear kappa-B (NF-kB), un factor de transcripci\u00f3n esencial de IL-6, incrementando la supervivencia animal con reducci\u00f3n de los niveles de IL-6 18 . Tocilizumab que bloquea la IL-6, se une al receptor de IL-6 tanto en forma soluble como unido a la membrana para inhibir se\u00f1ales mediadas por IL-6. Este f\u00e1rmaco ha sido aprobado por la FDA para el tratamiento de SLC asociado a terapia de c\u00e9lulas CAR-T.",
            "cite_spans": [
                {
                    "start": 590,
                    "end": 592,
                    "text": "18",
                    "ref_id": "BIBREF18"
                }
            ],
            "ref_spans": [],
            "section": "Tocilizumab, Inhibidor de la Interleucina 6 (IL-6)."
        },
        {
            "text": "Datos sobre el uso de esta mol\u00e9cula en el tratamiento de la infecci\u00f3n SARS-CoV-2 todav\u00eda son preliminares pero resultados prometedores han incitado a la Comisi\u00f3n China de Salud a actualizar su gu\u00eda nacional que incluye el tocilizumab para el tratamiento de COVID-19 grave 19 . Las gu\u00edas italianas tambi\u00e9n apoyan el uso de tocilizumab (a dosis de 8 mg/kg, con una segunda dosis 12 horas despu\u00e9s de la primera y una posible tercera despu\u00e9s de [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Inmunoglobulina Intravenosa y plasma de pacientes recuperados (\"plasma convaleciente\") Los individuos con un sistema inmune debilitado parecen estar en mayor riesgo de desarrollar complicaciones asociadas con COVID-19. La inmunoterapia usando IgG en combinaci\u00f3n con f\u00e1rmacos anti-virales pudieras ser usadas para tratar o prevenir COVID-19 y fortalecer nuestro sistema inmune en contra de este virus 28, 29 . Las inmunoglobulinas intravenosas (IVIG) han sido utilizadas para tratar a pacientes con inflamatorias cr\u00f3nicas y autoinmunes. Adem\u00e1s, estas han sido administradas como agentes anti-infecciosos en contra de virus, bacterias, hongos en modelos experimentales y en humanos 30 . Las IVIG pueden modular la respuesta inmune por varios mecanismos, incluyendo el bloqueo de varias citocinas pro-inflamatorias, receptores Fc, y mol\u00e9culas de adhesi\u00f3n leucocitarias, suprimiendo subtipos de c\u00e9lulas Th1 y Th17 y neutralizando autoanticuerpos patog\u00e9nicos 31 . Las IVIG tambi\u00e9n pueden expandir los linfocitos T reguladores 32 . Sin embargo, las IVIG tienen reacciones adversas. Durante el brote de SARS en 2003, la IVIG fue utilizada extensamente en Singapur. Sin embargo, un algunos pacientes cr\u00edticamente enfermos desarrollaron tromboembolismo venoso (TEV) incluyendo embolismo pulmonar a pesar del uso de heparina de bajo peso molecular (HBPM) profil\u00e1ctica 33 . Esto se debe al incremento de la viscosidad en estados hipercoagulables de pacientes con SARS.",
            "cite_spans": [
                {
                    "start": 272,
                    "end": 274,
                    "text": "19",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 441,
                    "end": 445,
                    "text": "[24]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 446,
                    "end": 450,
                    "text": "[25]",
                    "ref_id": null
                },
                {
                    "start": 451,
                    "end": 455,
                    "text": "[26]",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 456,
                    "end": 460,
                    "text": "[27]",
                    "ref_id": "BIBREF28"
                },
                {
                    "start": 461,
                    "end": 465,
                    "text": "[28]",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 466,
                    "end": 470,
                    "text": "[29]",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 471,
                    "end": 475,
                    "text": "[30]",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 476,
                    "end": 480,
                    "text": "[31]",
                    "ref_id": "BIBREF32"
                },
                {
                    "start": 481,
                    "end": 485,
                    "text": "[32]",
                    "ref_id": "BIBREF33"
                },
                {
                    "start": 486,
                    "end": 490,
                    "text": "[33]",
                    "ref_id": "BIBREF34"
                },
                {
                    "start": 491,
                    "end": 495,
                    "text": "[34]",
                    "ref_id": "BIBREF35"
                },
                {
                    "start": 496,
                    "end": 500,
                    "text": "[35]",
                    "ref_id": "BIBREF36"
                },
                {
                    "start": 501,
                    "end": 505,
                    "text": "[36]",
                    "ref_id": "BIBREF37"
                },
                {
                    "start": 906,
                    "end": 909,
                    "text": "28,",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 910,
                    "end": 912,
                    "text": "29",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 1186,
                    "end": 1188,
                    "text": "30",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 1460,
                    "end": 1462,
                    "text": "31",
                    "ref_id": "BIBREF32"
                },
                {
                    "start": 1527,
                    "end": 1529,
                    "text": "32",
                    "ref_id": "BIBREF33"
                },
                {
                    "start": 1864,
                    "end": 1866,
                    "text": "33",
                    "ref_id": "BIBREF34"
                }
            ],
            "ref_spans": [],
            "section": "Tocilizumab, Inhibidor de la Interleucina 6 (IL-6)."
        },
        {
            "text": "Las muestras de plasma en fase convaleciente ha sido usados para tratar SARS en Hong-Kong y China y pueden ser valiosas porque, a diferencia de las preparaciones IVIG est\u00e1ndares, presentan niveles altos de anticuerpos anti-SARS-CoV 34 . Pyrc y col., mostraron que el suero humano de adultos humanos inhibi\u00f3 la infecci\u00f3n por HCov-NL63 28 .",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Tocilizumab, Inhibidor de la Interleucina 6 (IL-6)."
        },
        {
            "text": "Adicionalmente, ellos describieron que las IVIG puede tambi\u00e9n neutralizar HCoV-NL63.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Tocilizumab, Inhibidor de la Interleucina 6 (IL-6)."
        },
        {
            "text": "Boukhvalova y col. 35 , demostraron que, en contraste los productos de IgG policlonacles terap\u00e9uticos comercialmente disponibles, IVIG obtenida de donadores con anticuerpos a Page 8 of 17 J o u r n a l P r e -p r o o f 8 t\u00edtulos altos en contra del virus sincitial respiratorio (VSR) tienen un gran potencial en mejorar el resultado de VSR en sujetos inmunocomprometidos, no solo controlando la replicaci\u00f3n viral pero tambi\u00e9n reduciendo el da\u00f1o del par\u00e9nquima pulmonar y el revestimiento epitelial de las v\u00edas respiratorias. El uso de plasma o suero convaleciente fue tambi\u00e9n sugerido por la OMS bajo la Red de Reguladores de Sangre cuando las vacunas y los f\u00e1rmacos anti-virales no estuvieran disponibles en un virus emergente. En la actual pandemia hay reportes de que el plasma convaleciente ha sido usado en China para tratar pacientes con COVID-19 36 . En un estudio piloto de 10 pacientes con COVID-19 grave, los investigadores colectaron plasta convaleciente con t\u00edtulos de anticuerpos neutralizantes de una diluci\u00f3n de 1:640 o m\u00e1s 37 . La transfusi\u00f3n de plasma convalecientes resulto sin eventos adversos serios en los receptores. Todos los 10 pacientes tuvieron mejor\u00eda de los s\u00edntomas (p.e. fiebre, tos, dificultad para respirar y dolor precordial) con 1-3 d\u00edas de la transfusi\u00f3n; ellos tambi\u00e9n mostraron mejora radiol\u00f3gica en las lesiones pulmonares. Igualmente se encontr\u00f3 en la mayor\u00eda una carga viral indetectable. La inmunoterapia con IgG pudiera ser empleada para neutralizar el virus causante de COVID-19. La eficiencia de IgG podr\u00eda mejorar si estos anticuerpos IgG inmunes fueran colectados de pacientes recuperados de COVID-19 en la misma ciudad, o \u00e1reas alrededor, como sujetos donadores que se han enfrentado al virus.",
            "cite_spans": [
                {
                    "start": 19,
                    "end": 21,
                    "text": "35",
                    "ref_id": "BIBREF36"
                },
                {
                    "start": 853,
                    "end": 855,
                    "text": "36",
                    "ref_id": "BIBREF37"
                }
            ],
            "ref_spans": [],
            "section": "Tocilizumab, Inhibidor de la Interleucina 6 (IL-6)."
        },
        {
            "text": "La af\u00e9resis terap\u00e9utica engloba un gran n\u00famero de t\u00e9cnicas que tienen como principal fundamento procesar la sangre de un paciente a trav\u00e9s de un dispositivo extracorp\u00f3reo con el objetivo de eliminar anticuerpos e inmunocomplejos preformados para evitar el da\u00f1o tisular, eliminar mediadores de la inflamaci\u00f3n como complemento y citocinas que podr\u00edan contribuir al da\u00f1o, aportar factores deficitarios 38 . Entre los diferentes tipos de af\u00e9resis, uno de los m\u00e1s utilizados son el recambio plasm\u00e1tico terap\u00e9utico y la inmunoadsorci\u00f3n. El 9 recambio plasm\u00e1tico terap\u00e9utico (RP) es una t\u00e9cnica de depuraci\u00f3n de la sangre extracorp\u00f3rea, mediante la cual se elimina el plasma. Se realiza la extracci\u00f3n de un volumen variable de plasma del paciente que es sustituido por soluciones de reposici\u00f3n que mantengan el volumen y la presi\u00f3n onc\u00f3tica. El t\u00e9rmino \u00abplasmaf\u00e9resis\u00bb debe reservarse para las situaciones en las que solo se lleve a cabo la eliminaci\u00f3n de plasma sin reposici\u00f3n, como es el caso de la donaci\u00f3n de plasma por af\u00e9resis para uso transfusional o posterior fraccionamiento industrial del plasma. Este procedimiento extrae menos cantidad de plasma (en torno 600 ml), sin soluci\u00f3n de reposici\u00f3n, en menos tiempo y con t\u00e9cnicas de separaci\u00f3n m\u00e1s simples que las utilizadas en el RP. La respuesta del hu\u00e9sped a la infecci\u00f3n se ha descrito e involucra una interacci\u00f3n compleja de tormenta de citocinas, inflamaci\u00f3n, disfunci\u00f3n endotelial, y coagulaci\u00f3n patol\u00f3gica. El intercambio plasm\u00e1tico es una v\u00eda que ofrece beneficio a m\u00faltiples niveles retirando citocinas inflamatorias, estabilizando las membranas endoteliales y reiniciando el estado hipercoagulable.",
            "cite_spans": [
                {
                    "start": 399,
                    "end": 401,
                    "text": "38",
                    "ref_id": "BIBREF39"
                }
            ],
            "ref_spans": [],
            "section": "Intercambio Plasm\u00e1tico"
        },
        {
            "text": "Busund y col. 39 , mostraron una tendencia hacia mejorar la mortalidad con RP terap\u00e9utico como tratamiento adyuvante en adultos con sepsis y fallo org\u00e1nico m\u00faltiple, en un ensayo cl\u00ednico controlado, mientras que un meta-an\u00e1lisis por Rimmer tambi\u00e9n mostr\u00f3 beneficio en la mortalidad en pacientes adultos 40 . Dirigiendo esta informaci\u00f3n, Patel y col. 41 , utilizaron el RP terap\u00e9utico durante la epidemia de influenza A H1N1 2009 en 3 pacientes pedi\u00e1tricos con un cuadro fulminante similar a la pandemia actual. Los 3 pacientes desarrollaron SIRA con compromiso hemodin\u00e1mico que continu\u00f3 al deterioro a pesar del tratamiento de rescate para SIRA incluyendo \u00f3xido n\u00edtrico inhalado y oxigenaci\u00f3n por membrana extracorp\u00f3rea (ECMO) veno-venosa. Los 3 pacientes tuvieron una recuperaci\u00f3n total de su enfermedad despu\u00e9s de recibir RP de rescate. Recientemente se describi\u00f3 a 3 pacientes con COVID-19 en Wuhan, China 42 , caracterizados por una inflamaci\u00f3n profunda y tratados con terapias de purificaci\u00f3n sangu\u00ednea, incluyendo RP y adsorci\u00f3n. Se mostr\u00f3 un efecto potencia en el manejo de tormenta de citocinas y anticuerpos patog\u00e9nicos. De estos 3 pacientes, 2 se mantuvieron un estado estable y pudieron ser egresados de la Unidad de Terapia Intensivo, mientras que uno desarroll\u00f3 Coagulaci\u00f3n Intravascular Diseminada (CID) y falleci\u00f3.",
            "cite_spans": [
                {
                    "start": 14,
                    "end": 16,
                    "text": "39",
                    "ref_id": "BIBREF40"
                },
                {
                    "start": 303,
                    "end": 305,
                    "text": "40",
                    "ref_id": "BIBREF41"
                },
                {
                    "start": 350,
                    "end": 352,
                    "text": "41",
                    "ref_id": "BIBREF42"
                }
            ],
            "ref_spans": [],
            "section": "Intercambio Plasm\u00e1tico"
        },
        {
            "text": "La enfermedad por COVID-19 grave frecuentemente se puede presentar una elevaci\u00f3n marcada de d\u00edmero D, trombocitopenia y alteraciones en la coagulaci\u00f3n que se considera ser reguladas por varias citosinas inflamatorias 43,44 y que correlacionan con mortalidad.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Terapia anti-tromb\u00f3tica"
        },
        {
            "text": "Otro biomarcador que se ha encontrado elevado en pacientes con COVID-19 grave es la ferritina 12 , la cual tambi\u00e9n se encuentra alterado en otras condiciones graves, incluyendo el SAF en su variedad m\u00e1s grave el SAF catastr\u00f3fico 45 . Recientemente un grupo de China describi\u00f3 3 casos con COVID-19 y anticuerpos antifosfol\u00edpidos 46 . Recientes declaraciones por la ISTH (International Society on Thrombosis and Haemostasis) y el ASH (American Society of Hematology) sugieren que todos los pacientes hospitalizados con Covid-19 deben recibir tromboprofilaxis, o anticoagulaci\u00f3n a dosis plena terap\u00e9uticas. Recientemente, se evalu\u00f3 en forma retrospectiva la eficacia de terapia anticoagulaci\u00f3n en pacientes con Covid-19. Se encontr\u00f3 una mortalidad a 28 d\u00edas m\u00e1s baja en los pacientes que utilizaron heparina (40%) comparado con los que no (64.2%) principalmente en aquellos con coagulopat\u00eda inducida por sepsis o con un d\u00edmero D marcadamente elevado 47 . En tabla 1 se sintetiza las recomendaciones anti-tromb\u00f3ticas de pacientes con Covid-19.",
            "cite_spans": [
                {
                    "start": 229,
                    "end": 231,
                    "text": "45",
                    "ref_id": "BIBREF47"
                },
                {
                    "start": 328,
                    "end": 330,
                    "text": "46",
                    "ref_id": "BIBREF49"
                },
                {
                    "start": 947,
                    "end": 949,
                    "text": "47",
                    "ref_id": "BIBREF50"
                }
            ],
            "ref_spans": [],
            "section": "Terapia anti-tromb\u00f3tica"
        },
        {
            "text": "El COVID-19 es una infecci\u00f3n viral con potencial complicaciones graves que pueden incrementar el riesgo de muerte en los pacientes infectados. Varias de estas alteraciones son secundarias a una respuesta inmune descontrolada donde una tormenta de citocinas juega con papel relevante, en forma similar la prevenci\u00f3n de complicaciones tromb\u00f3ticas a los que estos pacientes est\u00e1n expuestos. Aunque un tratamiento anti-viral y terapias de apoyo respiratorio son fundamentales del tratamiento en casos grave, es necesario ponderar el riesgo beneficio de terapias dirigidas al control de la respuesta inmune para disminuir la tasa.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusiones"
        },
        {
            "text": "La presente investigaci\u00f3n no ha recibido ayudas espec\u00edficas provenientes de agencias del sector p\u00fablico, del sector comercial o de entidades sin \u00e1nimo de lucro.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Financiaci\u00f3n"
        },
        {
            "text": "Los autores manifiestan que no tienen ning\u00fan conflicto de intereses",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conflicto de intereses"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Current concepts in the diagnosis and management of cytokine release syndrome",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "W"
                    ],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Gardner",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "L"
                    ],
                    "last": "Porter",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "U"
                    ],
                    "last": "Louis",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Ahmed",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Jensen",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Blood",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Cai",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xia",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "JAMA Intern Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Incidence of thrombotic complications in critically ill ICU patients with COVID-19",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "A"
                    ],
                    "last": "Klok",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Kruip",
                    "suffix": ""
                },
                {
                    "first": "Njm",
                    "middle": [],
                    "last": "Van Der Meer",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Arbous",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Gommers",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "M"
                    ],
                    "last": "Kant",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China",
            "authors": [],
            "year": 2020,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)",
            "authors": [
                {
                    "first": "Y-H",
                    "middle": [],
                    "last": "Jin",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Cai",
                    "suffix": ""
                },
                {
                    "first": "Z-S",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                },
                {
                    "first": "Y-P",
                    "middle": [],
                    "last": "Fan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Mil Med Res",
            "volume": "7",
            "issn": "1",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "D"
                    ],
                    "last": "Russell",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "E"
                    ],
                    "last": "Millar",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "K"
                    ],
                    "last": "Baillie",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "473--478",
            "other_ids": {
                "DOI": [
                    "10.1016/S0140-6736(20)30317-2"
                ]
            }
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell research. England",
            "volume": "30",
            "issn": "",
            "pages": "269--71",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial",
            "authors": [],
            "year": 2020,
            "venue": "Int J Antimicrob Agents",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Tian",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Biosci Trends",
            "volume": "14",
            "issn": "1",
            "pages": "72--75",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Magagnoli",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Narendran",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Pereira",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Cummings",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "W"
                    ],
                    "last": "Hardin",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "S"
                    ],
                    "last": "Sutton",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv [Internet",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Wan",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Yi",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Fan",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Lv",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Guo",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Pathological findings of COVID-19 associated with acute respiratory distress syndrome",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "8",
            "issn": "",
            "pages": "420--422",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study",
            "authors": [
                {
                    "first": "Jsm",
                    "middle": [],
                    "last": "Peiris",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Chu",
                    "suffix": ""
                },
                {
                    "first": "Vcc",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "S"
                    ],
                    "last": "Chan",
                    "suffix": ""
                },
                {
                    "first": "Ifn",
                    "middle": [],
                    "last": "Hung",
                    "suffix": ""
                },
                {
                    "first": "Llm",
                    "middle": [],
                    "last": "Poon",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Lancet",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Med Virol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Immunotherapeutic implications of IL-6 blockade for cytokine storm",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tanaka",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Narazaki",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Kishimoto",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Immunotherapy",
            "volume": "8",
            "issn": "8",
            "pages": "959--70",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Inhibition of NF-kappaB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Dediego",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Nieto-Torres",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Regla-Nava",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Jimenez-Guardeno",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Fernandez-Delgado",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Fett",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "J Virol",
            "volume": "88",
            "issn": "2",
            "pages": "913--937",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia",
            "authors": [],
            "year": null,
            "venue": "Trial Version",
            "volume": "7",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Linee guida sulla gestione terapeutica e di supporto per pazienti con infezione da coronavirus COVID-19",
            "authors": [],
            "year": null,
            "venue": "SIMIT Societ\u00e0 Italiana di Malattie Infettive e Tropicali",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report",
            "authors": [
                {
                    "first": "J-M",
                    "middle": [],
                    "last": "Michot",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Albiges",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Chaput",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Saada",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Pommeret",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Griscelli",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Annals of oncology : official journal of the European Society for Medical Oncology. England",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Autoimmun",
            "volume": "102452",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Mcgoogan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "M"
                    ],
                    "last": "Eloseily",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Weiser",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "B"
                    ],
                    "last": "Crayne",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Haines",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Mannion",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Stoll",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Arthritis Rheumatol",
            "volume": "72",
            "issn": "2",
            "pages": "326--360",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial",
            "authors": [],
            "year": 2016,
            "venue": "Crit Care Med",
            "volume": "44",
            "issn": "2",
            "pages": "275--81",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Maschalidi",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "E"
                    ],
                    "last": "Sepulveda",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Garrigue",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Fischer",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "De Saint Basile",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Blood",
            "volume": "128",
            "issn": "1",
            "pages": "60--71",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "B"
                    ],
                    "last": "Jordan",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Hildeman",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Kappler",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Marrack",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Blood",
            "volume": "104",
            "issn": "3",
            "pages": "735--778",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Inhibition of human coronavirus NL63 infection at early stages of the replication cycle",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Pyrc",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Bosch",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Berkhout",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "F"
                    ],
                    "last": "Jebbink",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Dijkman",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Rottier",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Antimicrob Agents Chemother",
            "volume": "50",
            "issn": "6",
            "pages": "2000--2008",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Coronavirus Associated Fulminant Myocarditis Successfully Treated With Intravenous Immunoglobulin and Extracorporeal Membrane Oxygenation",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Rao",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Sasser",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Diaz",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Sharma",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Alten",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "IVIG-mediated protection against necrotizing pneumonia caused by MRSA",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "A"
                    ],
                    "last": "Diep",
                    "suffix": ""
                },
                {
                    "first": "Vtm",
                    "middle": [],
                    "last": "Le",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Badiou",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "N"
                    ],
                    "last": "Le",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "Pinheiro",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "H"
                    ],
                    "last": "Duong",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Sci Transl Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barre syndrome patients",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Maddur",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Rabin",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Hegde",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Bolgert",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Guy",
                    "suffix": ""
                },
                {
                    "first": "J-M",
                    "middle": [],
                    "last": "Vallat",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Immunol Res",
            "volume": "60",
            "issn": "2-3",
            "pages": "320--329",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Trinath",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Hegde",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Sharma",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Maddur",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Rabin",
                    "suffix": ""
                },
                {
                    "first": "J-M",
                    "middle": [],
                    "last": "Vallat",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Blood",
            "volume": "122",
            "issn": "8",
            "pages": "1419--1446",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome",
            "authors": [
                {
                    "first": "Twk",
                    "middle": [],
                    "last": "Lew",
                    "suffix": ""
                },
                {
                    "first": "T-K",
                    "middle": [],
                    "last": "Kwek",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Tai",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Earnest",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Loo",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Singh",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "JAMA",
            "volume": "290",
            "issn": "3",
            "pages": "374--80",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "Deployment of convalescent plasma for the prevention and treatment of COVID-19",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "M"
                    ],
                    "last": "Bloch",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Shoham",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Casadevall",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "S"
                    ],
                    "last": "Sachais",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Shaz",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Winters",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Clin Invest",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Boukhvalova",
                    "suffix": ""
                },
                {
                    "first": "Jcg",
                    "middle": [],
                    "last": "Blanco",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "R"
                    ],
                    "last": "Falsey",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Mond",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Bone Marrow Transplant",
            "volume": "51",
            "issn": "1",
            "pages": "119--145",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "China puts 245 COVID-19 patients on convalescent plasma therapy",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Xinhua",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Duan",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Qu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Schwartz",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Padmanabhan",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Aqui",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Balogun",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Connelly-Smith",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Delaney",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "J Clin Apher",
            "volume": "31",
            "issn": "3",
            "pages": "149--62",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Busund",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Koukline",
                    "suffix": ""
                },
                {
                    "first": "U",
                    "middle": [],
                    "last": "Utrobin",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Nedashkovsky",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Intensive Care Med",
            "volume": "28",
            "issn": "10",
            "pages": "1434--1443",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Rimmer",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "L"
                    ],
                    "last": "Houston",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Kumar",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "M"
                    ],
                    "last": "Abou-Setta",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Friesen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Marshall",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Crit Care",
            "volume": "18",
            "issn": "6",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A--an associated respiratory failure and hemodynamic shock",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Patel",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Nandwani",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Vanchiere",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Conrad",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "K"
                    ],
                    "last": "Scott",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Pediatr Crit Care Med",
            "volume": "12",
            "issn": "2",
            "pages": "87--96",
            "other_ids": {}
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Xia",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "United States; 2020",
            "authors": [],
            "year": null,
            "venue": "Clinical immunology",
            "volume": "214",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Yin",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Thromb Thrombolysis",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Lippi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Plebani",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "M"
                    ],
                    "last": "Henry",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Clin Chim Acta",
            "volume": "506",
            "issn": "",
            "pages": "145--153",
            "other_ids": {}
        },
        "BIBREF47": {
            "ref_id": "b47",
            "title": "Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS)",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Agmon-Levin",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Rosario",
                    "suffix": ""
                },
                {
                    "first": "B-Sp",
                    "middle": [],
                    "last": "Katz",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Zandman-Goddard",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Meroni",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Cervera",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF49": {
            "ref_id": "b49",
            "title": "Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Xiao",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Xia",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF50": {
            "ref_id": "b50",
            "title": "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Bai",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gong",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Thromb Haemost",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF51": {
            "ref_id": "b51",
            "title": "COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Bikdeli",
                    "suffix": ""
                },
                {
                    "first": "M V",
                    "middle": [],
                    "last": "Madhavan",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Jimenez",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Chuich",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Dreyfus",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Driggin",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Am Coll Cardiol",
            "volume": "27284",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "14 , lo que sugiere una respuesta inmune descontrolada.",
            "latex": null,
            "type": "figure"
        }
    },
    "back_matter": []
}